Cytyc Corporation Announces Executive Promotions; Dan Levangie Named Chief Operating Officer.

Business/Technology Editors

BOXBOROUGH, Mass.--(BUSINESS WIRE)--Feb. 1, 2001

Cytyc Corporation (Nasdaq:CYTC) today announced the promotion of Daniel J. Levangie to executive vice president and chief operating officer. Mr. Levangie will oversee worldwide business activities, including sales, marketing, manufacturing, engineering, research and development, and customer service. His promotion was approved by Cytyc's Board of Directors this week and is effective immediately.

"This is a well-deserved and well-earned promotion," said Patrick J. Sullivan, Cytyc's president and chief executive officer. "When Dan joined Cytyc in 1992, we had a six person sales team and a Pap test market share of zero. Today, thanks in large part to Dan's leadership, we have built a world-class sales and marketing organization and, as of the fourth quarter of last year, had achieved a 36 percent share of the Pap test market. We look forward to Dan's ongoing contributions to Cytyc."

Mr. Levangie has served in a number of key executive roles at Cytyc. Prior to joining Cytyc, Mr. Levangie held sales and marketing management positions at Abbott Laboratories.

In addition, Cytyc's Board of Directors this week approved the appointment of C. William McDaniel and Patrick J. Sullivan to the position of vice chairmen of the Cytyc Board of Directors. Mr. McDaniel is currently a non-employee member of Cytyc's Board of Directors and was an early investor of Cytyc. Mr. Sullivan will retain his current position of president and chief executive officer of the Company. Monroe E. Trout, M.D., will remain chairman of the Board of Directors.

Cytyc Corporation develops, manufactures, and markets the ThinPrep(R) System for medical diagnostic applications. The ThinPrep System consists of the ThinPrep(R) 2000 Processor, ThinPrep(R) 3000 Processor, and related reagents, filters, and other supplies.

Cytyc(R), ThinPrep(R), and PreservCyt(R) are registered trademarks and ThinPrep(R) Pap Test(TM) is a trademark of Cytyc Corporation.

Forward-looking statements in this press release are made pursuant to the provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding management's expectations for future growth and objectives for future management and operations, constitute forward-looking statements which involve risks and uncertainties which could cause actual results to differ, including, without limitation, risks associated with the Company's dependence on a single product, uncertainty of market acceptance and additional cost, dependence on proprietary technology, dependence on timely and adequate levels of third-party reimbursement, dependence on key personnel, management of growth, limited marketing and sales experience, and limited number of customers and lengthy sales cycle, as well as risks of downturns in economic conditions generally, and in the healthcare industry specifically, risks associated with competition and competitive pricing pressures, potential liabilities and costs associated with litigation, and other risks detailed in the Company's filings with the Securities and Exchange Commission, including in its 1999 Form 10-K filed with the Commission.